A prospective clinical trial of green tea for hormone refractory prostate cancer: An evaluation of the complementary/alternative therapy approach
- 30 April 2005
- journal article
- clinical trial
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 23 (2) , 108-113
- https://doi.org/10.1016/j.urolonc.2004.10.008
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Molecular Targets for Green Tea in Prostate Cancer PreventionJournal of Nutrition, 2003
- Complementary and alternative medicine in prostate cancer.Current Oncology Reports, 2001
- Phase I Trial of Oral Green Tea Extract in Adult Patients With Solid TumorsJournal of Clinical Oncology, 2001
- Alternative medicine use in patients with localized prostate carcinoma treated with curative intentCancer, 1999
- PREVALENCE AND PATTERNS OF THE USE OF COMPLEMENTARY THERAPIES AMONG PROSTATE CANCER PATIENTS: AN EPIDEMIOLOGICAL ANALYSISJournal of Urology, 1999
- Induction of apoptosis in prostate cancer cell lines by the green tea component, (−)-epigallocatechin-3-gallateCancer Letters, 1998
- Green Tea Constituent Epigallocatechin-3-Gallate and Induction of Apoptosis and Cell Cycle Arrest in Human Carcinoma CellsJNCI Journal of the National Cancer Institute, 1997
- Prevention of photocarcinogenesis by topical administration of pure epigallocatechin gallate isolated from green teaNutrition and Cancer, 1996
- Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallateCancer Letters, 1995
- Tea and CancerJNCI Journal of the National Cancer Institute, 1993